Haemophilus Influenza B IgG antibodies Test

Haemophilus influenzae is a gram-negative bacteria that is present in approximately three-quarters of children and adults. In infants and young children, Haemophilus influenzae, especially type B, may cause bacteraemia and meningitis. In children and older individuals Haemophilus influenzae may cause respiratory tract infections. One of the great advances in modern medicine has been the development of an effective vaccine against HIB. A patient's immunological response to HIB vaccine can be determined by measuring anti-HIB IgG antibody using this EIA technique.

Collect: Serum separator tube. 'Pre' and 30-day 'post' Haemophilus influenzae b vaccination specimens should be submitted together for testing. 'Post' specimen should be drawn 30 days after immunization and must be received within 60 days of 'pre' specimen. Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL).

Storage/Transport Temperature: Refrigerated. Unacceptable Conditions: Plasma or other body fluids. Contaminated, haemolysed or, severely lipemia specimens. Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles).

Evaluate the ability of a patient to produce antibody to a protein conjugated bacterial (H. influenza) vaccine to rule out antibody deficiency. Assessing a patient's immunological (IgG) response to Haemophilus influenzae type B (HIB) vaccine. Assessing immunity against HIB Aiding in the evaluation of immunodeficiency

Microwells are pre-coated with the Haemophilus influenzae type B (HIB) capsular polysaccharide antigen conjugated to human serum albumin. The calibrators, controls, and diluted patient specimens are added to the wells and antibodies recognizing the HIB antigen bind during the first incubation. After washing the wells to remove all unbound proteins, purified peroxidase-labelled rabbit antihuman IgG (gamma chain specific) conjugate is added. The conjugate binds to the captured human antibody and the excess unbound conjugate is removed by a further wash step. The bound conjugate is visualized with 3, 3’, 5, 5’ tetramethylbenzidine (TMB) substrate, which gives a blue reaction product, the intensity of which is proportional to the concentration of antibody in the specimen. Phosphoric acid is added to each well to stop the reaction. This produces a yellow end point color, which is read at 450 nm.